Literature DB >> 15293007

[Synaptic vesicle proteins and psychiatric disorders].

S Rapp1, J Thome.   

Abstract

Synaptic vesicle proteins modulate the release of neurotransmitters in the synaptic cleft via regulation of vesicle transport, membrane fusion and exocytosis. Due to their relevance for neural and synaptic plasticity, they represent an important object of molecular psychiatric research. There is increasing evidence that they play a significant role in the pathophysiology of several psychiatric disorders. Furthermore, psychotropic drugs differentially modify the expression of synaptic vesicle proteins; thus, this group of molecules is also of considerable interest from a therapeutic point of view.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15293007     DOI: 10.1007/s00115-003-1673-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  37 in total

Review 1.  Synaptic vesicle proteins and neuronal plasticity in adrenergic neurons.

Authors:  X E Hou; A Dahlström
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

Review 2.  [Molecular aspects of antidepressive therapy. Transsynaptic effects on signal transduction, gene expression and neuronal plasticity].

Authors:  J Thome; R S Duman; F A Henn
Journal:  Nervenarzt       Date:  2002-07       Impact factor: 1.214

3.  Identification of synaptophysin as a hexameric channel protein of the synaptic vesicle membrane.

Authors:  L Thomas; K Hartung; D Langosch; H Rehm; E Bamberg; W W Franke; H Betz
Journal:  Science       Date:  1988-11-18       Impact factor: 47.728

4.  Inhibition of neurotransmitter release by synthetic proline-rich peptides shows that the N-terminal domain of vesicle-associated membrane protein/synaptobrevin is critical for neuro-exocytosis.

Authors:  F Cornille; F Deloye; M C Fournié-Zaluski; B P Roques; B Poulain
Journal:  J Biol Chem       Date:  1995-07-14       Impact factor: 5.157

5.  Reduction of the synaptophysin level but normal levels of glycerophospholipids in the gyrus cinguli in schizophrenia.

Authors:  Mikael Landén; Pia Davidsson; Carl-Gerhard Gottfries; Jan-Eric Månsson; Kaj Blennow
Journal:  Schizophr Res       Date:  2002-05-01       Impact factor: 4.939

6.  Inducible and brain region-specific CREB transgenic mice.

Authors:  Norio Sakai; Johannes Thome; Samuel S Newton; Jingshan Chen; Max B Kelz; Cathy Steffen; Eric J Nestler; Ronald S Duman
Journal:  Mol Pharmacol       Date:  2002-06       Impact factor: 4.436

7.  Temporal cortex synaptophysin mRNA is reduced in Alzheimer's disease and is negatively correlated with the severity of dementia.

Authors:  J M Heffernan; S L Eastwood; Z Nagy; M W Sanders; B McDonald; P J Harrison
Journal:  Exp Neurol       Date:  1998-04       Impact factor: 5.330

8.  Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia.

Authors:  S L Eastwood; P W Burnet; P J Harrison
Journal:  Neuroscience       Date:  1995-05       Impact factor: 3.590

9.  Synapsin I (protein I) in different brain regions in senile dementia of Alzheimer type and in multi-infarct dementia.

Authors:  E Perdahl; R Adolfsson; I Alafuzoff; K A Albert; E J Nestler; P Greengard; B Winblad
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

10.  Differential regulation of synaptic vesicle proteins by antidepressant drugs.

Authors:  S Rapp; M Baader; M Hu; C Jennen-Steinmetz; F A Henn; J Thome
Journal:  Pharmacogenomics J       Date:  2004       Impact factor: 3.550

View more
  1 in total

1.  A cell culture model for investigation of synapse influenceability: epigenetics, expression and function of gene targets important for synapse formation and preservation in SH-SY5Y neuroblastoma cells differentiated by retinoic acid.

Authors:  Kirsten Jahn; C Wieltsch; N Blumer; M Mehlich; H Pathak; A Q Khan; H Hildebrandt; H Frieling
Journal:  J Neural Transm (Vienna)       Date:  2017-09-08       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.